Minced skin grafting (MG) is a procedure that involves mincing of the harvested skin and grafting it back onto the wounds. We aimed to investigate whether MG reduces the healing time and improves the sequential postoperative appearance of donor sites.
A single-center, two-treatment, half-side comparative study was performed. The split-thickness skin remaining after grafting was minced until pasty. The small pasty graft mass was uniformly spread on half of the entire donor site. MG was not performed on the other side. The data from 30 patients were used for analysis.
The average time to complete healing of the donor sites in the MG and control groups was 9.4±2.5 and 12.4±3.6 days, respectively. The difference in the healing time between the 2 groups was statistically significant (p<0.001). Three blinded surgeons used a scale to grade photographs according to the degree of conspicuous donor sites in comparison with the normal skin around the donor sites. All observers reported that the differences in donor site appearance between the MG and control groups were statistically significant at postoperative months 1 and 2, and two observers reported that the differences in donor site appearance were significant at months 4, 6, and 12. The differences in the number of patients with donor site dyspigmentation between the MG and control groups at 12 months were statistically significant (p<0.05).
This prospective half-side comparative trial demonstrates that MG promotes wound healing and improves donor site appearance after split-thickness skin grafting.
Department of Plastic Surgery, Kanazawa Medical University; Ishikawa, Japan
Financial Disclosure Statement: All authors declare that there are no conflicts of interest.
Author’s role/participation in authorship of the manuscript: Toru Miyanaga contributed in the core writing of the report. Miyuki Kishibe, Takayoshi Kaneko, and Fumiya Kinoshita were observers. Masahiro Yamashita and Kenichi Shimada collected the data. All authors interpreted the data and reviewed the final draft.
The study was conducted in compliance with the Declaration of Helsinki and followed a protocol approved by our institutional review board (IRB).
Clinical trial registration: The study was registered in the UMIN Clinical Trials Registry (http://www.umin.ac.jp/ctr) on August 25, 2018, with registration number of 000033890.
Corresponding author: Toru Miyanaga, MD, PhD, Kanazawa Medical University, 1-1 Daigaku, Uchinada, Kahoku, Ishikawa 920-0293 Japan. email@example.com